Zevra Therapeutics CFO to Depart by Year-End

By Hao Liu • Friday, November 21 15:37 • Permanent Link

Zevra Therapeutics, Inc. has announced the upcoming departure of its Chief Financial Officer and Treasurer, R. Laduane Clifton, with his last day set for December 31, 2025. Neil F. McFarlane, the company's CEO and President, expressed gratitude for Clifton's leadership, acknowledging his impact on the company's transition from a developmental stage to a commercial-stage company focused on rare diseases.

Under Clifton's tenure since 2015, Zevra has seen significant financial progress, laying a strong foundation for its future growth. Despite the impending departure, Clifton expressed confidence in the company's sustained success as he moves on to new opportunities.

Zevra Therapeutics, Inc. is actively searching for a replacement for the CFO position.

As a commercial-stage company, Zevra is dedicated to addressing unmet needs in the treatment of rare diseases, striving to provide life-changing therapeutics to this community. The company employs unique, data-driven strategies in both development and commercialization to overcome the challenges of drug development and make new therapies available to those living with rare diseases. Today the company's shares have moved -5.53% to a price of $8.55. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.